Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 crossover trial for patient-reported dyspnea in moderate-to-severe COPD
2011-000229-63Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Started Jun 2011; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-000229-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000229-63.